2The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative north scandinavian enalapril survival study (CONSENSUS). N Engl J Med, 1987,316:1429 - 1435.
3Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American college of cardiology/American heart association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure) : developed in collaboration with the American college of chest physicians and the international society for heart and lung transplantation: endorsed by the heart rhythm society. Circulation,2005,112 (12) .e154 - e235.
4Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005) : The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J,2005,26(11) :1115 - 1140.
5Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure,left ventricular dysfunction, or both. N Engl J Med,2003,349 (20) :1893 - 1906.
6Granger CB,McMurrary JJ,Yusuf S,et al. Effects of candesartan in patients with chronic heart failure and reduced left - ventricular systolic function intolerant to angiotensin - converting - enzyme inhibitors: the CHARM - Alternative trial. Lancet, 2003,362 (9386) :772 - 776.
7Cohn JN,Tognoni G, Valsartan Heart Failure Trail Investigators. A randomized trial of theangiotensin - receptor blocker valsartan in chronic heart failure. N Engl J Med, 2001,345 (23) : 1667 - 1675.
8Pitt B,Segal R, Martiniez FA, et al. Randomized trial of losartan versus capital in patients over 65 with heart failure. Lancet, 1997,349(9054) : 747 - 755.
9Pitt B, Poole-Wilson PA,Segal R,et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure:randomised trial:the losartan heart failure survival study ELITE Ⅱ. Lancet, 2000, 355 (9215):1582-1587.
二级参考文献6
1Goldstein S, Ali AS, Sabbah H, et al. Ventricular remodeling. Mechanism and prevention. Cardiol Clin, 1998,16(4):623-632.
2Dzau VJ, Hirsch AT. Emerging role of tissue rennin-angiotensin systems in congestive heart failure. Eur Heart J, 1990,11 (Suppl B) :65-71.
3Smits JF,van Krimpen C, Schoemaker RG, et al. Angiotensin Ⅱ receptor blockade after myocardial infarction in rats:effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content. J Cardiovasc Pharmacol, 1992,20(5) :772-778.
4Taylor K, Patten RD, Smith JJ, et al. Divergent effects of angiotensin-converting enzyme inhibition and angiotensin Ⅱ receptor antagonism on myocardial cellular proliferation and collagen deposition after myocardial infarction in rats. J Cardiovasc pharmacol, 1998 ,31 (5) :654-660.
5Jalowy A, Schulz R, Dorge H, et al. Infarct size reduction by ATI-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs. JAm Coil Cardiol, 1998 ,32(4): 1787-1796.
6Goodfriend TL, Elliott ME, Catt KJ, et al. Angiotensin receptors and their antagonist. N Engl J Med, 1996,334(25),1649-1654.
